@article {47565,
	title = {Macular telangiectasia type 1 managed with long-term aflibercept therapy.},
	journal = {Ophthalmic Surgery, Lasers and Imaging Retina},
	volume = {47},
	year = {2016},
	month = {2016 Jun},
	pages = {593-5},
	abstract = {<p>A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption.</p>
},
	doi = {10.3928/23258160-20160601-14},
	author = {Kovach, Jaclyn L and Hess, Harald F and Rosenfeld, Philip J}
}
